Exelixis Inc

EXELNASDAQ

Healthcare · Biological Products, (no Diagnostic Substances)

Market cap

$12.60B

Employees

1,077

Exchange

NASDAQ

Headquarters

ALAMEDA, CA

About Exelixis Inc

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Industry

Biological Products, (no Diagnostic Substances)

Sector

Healthcare

Country

US

Website

www.exelixis.com